Eagan RT 1976.

Study characteristics
Methods	RCT Randomisation not described ‐ stratified by site Groups fairly comparable ‐ Single group was younger and closer to menopause
Participants	39 women previously treated and failed CT Anthracycline and Taxane naive 100% MBC Unclear as to whether pre‐treatment was as adjuvant treatment or treatment for MBC Assessable no: 1) n = 19 2) n = 20
Interventions	ETO (VP‐16) vs V1+A 1) VP‐ 16 ‐ slow infusion over 30‐45 minutes on days 1,3,5, repeated every 4‐5 weeks 2) Vincristine + Adriamycin ‐ 1.5mg V1 IV on days 1 and 2 and A 45mg/m2 IV on day 3 Treatment repeated every 4‐5 weeks All drug dosages adjusted to produce adequate but clinically tolerable effects
Outcomes	No survival curves or TTP curves Response (PR only) 1) 2/19 2) 4/20 Toxicity: Leukopenia 1) 16/19 2) 18/20 Alopecia 1) 17/19 2) 19/20 Toxic death 1) 0 2) 1 (CNS Haemorrhage)
Notes	Not ITT ‐ 42 patients entered the trial ‐ 3 patients disqualified post randomisation due to protocol violations. Randomised numbers not provided by group Crossover on treatment failure
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported states 'partially randomised'
Allocation concealment (selection bias)	Unclear risk	Not reported
Incomplete outcome data (attrition bias) All outcomes	High risk	Some missing outcome data but not enough information to fully assess
Selective reporting (reporting bias)	High risk	The study fails to report survival or TTP